Jacobs Levy Equity Management
LFCR icon

Jacobs Levy Equity Management’s Lifecore Biomedical LFCR Stock Holding History

Jacobs Levy Equity Management’s Portfolio LFCR Stock Details LFCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-42,074
Closed -$207K – 1001
2024
Q3 		$207K Buy
+42,074
New +$220K ﹤0.01% 921
2022
Q3 		– Sell
-28,549
Closed -$285K – 1100
2022
Q2 		$285K Sell
28,549
-221,883
-89% -$2.2M ﹤0.01% 933
2022
Q1 		$2.9M Buy
250,432
+79,558
+47% +$886K 0.02% 541
2021
Q4 		$1.9M Buy
170,874
+1,199
+0.7% +$11.6K 0.01% 633
2021
Q3 		$1.56M Sell
169,675
-4,786
-3% -$52.1K 0.01% 663
2021
Q2 		$1.96M Buy
174,461
+8,052
+5% +$92.8K 0.01% 599
2021
Q1 		$1.76M Buy
166,409
+94,064
+130% +$1.06M 0.01% 627
2020
Q4 		$785K Buy
72,345
+24,013
+50% +$248K 0.01% 771
2020
Q3 		$470K Buy
+48,332
New +$460K ﹤0.01% 804
2020
Q1 		– Sell
-11,588
Closed -$131K – 1050
2019
Q4 		$131K Buy
+11,588
New +$123K ﹤0.01% 966
2018
Q4 		– Sell
-13,400
Closed -$193K – 1031
2018
Q3 		$193K Buy
+13,400
New +$185K ﹤0.01% 932
2013
Q4 		– Sell
-10,800
Closed -$132K – 990
2013
Q3 		$132K Sell
10,800
-531
-5% -$7.41K ﹤0.01% 882
2013
Q2 		$150K Buy
+11,331
New +$157K ﹤0.01% 919

Other funds holding LFCR

WC
Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return
LPAM
Legion Partners Asset Management Los Angeles, California $138M AUM 53.69% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
GRIM
Greenhaven Road Investment Management Greenwich, Connecticut $145M AUM 13.76% 1-Year Est. Return
3C
325 Capital New York $274M AUM 49.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Jacobs Levy Equity Management's LFCR Position: Q4 2024 in Review

Jacobs Levy Equity Management sold out of Lifecore Biomedical (LFCR) in Q4 2024, closing a stake of 42,074 shares — an estimated $207K sold.

Jacobs Levy Equity Management first reported a position in LFCR in Q2 2013 and held it in 13 quarters. The position peaked at $2.9M in Q1 2022. 77 funds tracked by Wall St. Rank hold LFCR as of Q4 2024.

  • Jacobs Levy Equity Management reported no remaining Lifecore Biomedical position as of Q4 2024 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 42,074 Lifecore Biomedical shares in Q4 2024, an estimated $207K.
  • Jacobs Levy Equity Management first reported a position in Lifecore Biomedical in Q2 2013 and held it in 13 quarters.
  • Jacobs Levy Equity Management's Lifecore Biomedical position peaked at $2.9M in Q1 2022.
  • 77 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q4 2024.

Based on Jacobs Levy Equity Management's 13F filing for Q4 2024, filed 14 Feb 2025.